MDA 19|1048973-47-2|-陌孚医药/Medlife

您当前的位置：

MDA 19

目录号: PL13529 纯度: ≥98%

CAS No. :1048973-47-2

商品编号	规格	价格	会员价
PL13529-5mg	5mg	¥1414.00	请登录
PL13529-10mg	10mg	¥2057.00	请登录
PL13529-50mg	50mg	¥8229.00	请登录
PL13529-100mg	100mg	询价	询价
PL13529-200mg	200mg	询价	询价
PL13529-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1555.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	MDA 19
中文别名	n’-[(3z)-1-己基-2-氧代-1,2-二氢-3H-吲哚-3-基idene]苯并肼;苯甲酸 (2Z)-2-(1-己基-1,2-二氢-2-氧代-3H-吲哚-3-亚基)肼;N'-(1-己基-2-氧代吲哚啉-3-基亚甲基)苯甲酰肼;MDA 19
英文名称	MDA 19
英文别名	N'-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazide;MDA 19;1,2,4-Triazine-6-carboxaldehyde, 2,3,4,5-tetrahydro-3,5-dioxo-;2-(6benzyloxy-3-oxo-3H-xanthen-9-yl)-benzyl ester;ACMC-20m1q2;AG-H-98079;benzoic acid (1-n-hexyl-2-oxo-1,2-dihydroindol-3-ylidene)hydrazide;CTK3F2017;dibenzylfluorescein;MDA-19;N'-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide;O,O'-Dibenzylfluorescein;O-benzylfluorescein benzyl ester;(Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide;N-[(Z)-(1-Hexyl-2-oxo-indolin-3-ylidene)aMino]benzaMide;N'-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide;Benzoic acid (2Z)-2-(1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide;MDA 19 (Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
Cas No.	1048973-47-2
分子式	C₂₁H₂₃N₃O₂
分子量	349.43
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	MDA 19 是一种有效和选择性的人类大麻素受体 2 (CB2) 激动剂，K_i 值为 43.3 nM。MDA 19 在神经性疼痛的大鼠模型中具有抗痛觉过敏作用，并且不影响大鼠的运动能力。
生物活性	MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.
性状	Solid
体外研究(In Vitro)	MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3,5-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemi [2]. Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.

溶解度数据	In Vitro: DMSO : 14.29 mg/mL (40.90 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation